{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:36:04Z","timestamp":1792427764790,"version":"4.5.0"},"reference-count":80,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Medicina"],"abstract":"<jats:p>Asthma is a chronic inflammatory disease with a heterogeneous course, often progressing silently from mild symptoms to severe, treatment-refractory disease. Current guidelines recommend biologic therapies after failure of high-dose inhaled corticosteroids and additional controllers, typically in patients with frequent exacerbations. This reactive approach may delay intervention until irreversible airway remodeling has occurred, limiting the potential benefits of biologic therapy. Therefore, severe asthma may be envisioned as the consequence of missed opportunities for early interventions. Early initiation of biologic therapy\u2014guided by biomarkers such as blood eosinophil count and fractional exhaled nitric oxide (FeNO), as well as symptom burden and risk of lung function decline\u2014may prevent progression to severe asthma and improve remission rates. This position paper advocates for a shift from severity-based to risk-based treatment strategies, recommending earlier biomarker assessment, redefinition of escalation criteria, and clinical trials designed to evaluate biologics in symptomatic non-exacerbating patients. By recognizing persistent inflammation and progression risk earlier in the disease course, clinicians may have a critical opportunity to alter the trajectory of asthma, reduce long-term morbidity, and achieve sustained control before irreversible damage occurs.<\/jats:p>","DOI":"10.3390\/medicina61101797","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T08:10:51Z","timestamp":1759738251000},"page":"1797","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Early Initiation of Biologic Therapies to Prevent Severe Asthma Progression"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-8508-7728","authenticated-orcid":false,"given":"Alessandra","family":"Tomasello","sequence":"first","affiliation":[{"name":"Division of Respiratory Medicine, PROMISE Department, \u201cPaolo Giaccone\u201d University Hospital, University of Palermo, 90127 Palermo, Italy"},{"name":"Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8609-0814","authenticated-orcid":false,"given":"Alida","family":"Benfante","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, PROMISE Department, \u201cPaolo Giaccone\u201d University Hospital, University of Palermo, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7277-699X","authenticated-orcid":false,"given":"Stefania","family":"Principe","sequence":"additional","affiliation":[{"name":"Amsterdam UMC, Department of Pulmonary Medicine, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6400-6573","authenticated-orcid":false,"given":"Nicola","family":"Scichilone","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, PROMISE Department, \u201cPaolo Giaccone\u201d University Hospital, University of Palermo, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"ref_1","unstructured":"Global Initiative for Asthma (2025, July 06). Global Strategy for Asthma Management and Prevention, 2025. [Internet]. Available online: www.ginasthma.org."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Backer, V., Gibson, P.G., and Pavord, I.D. (2023). The Asthmas: A Precision Medicine Approach to Treatable Traits, Diagnosis and Management, Taylor & Francis. [1st ed.].","DOI":"10.1201\/9780429330292"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.21037\/atm-22-5095","article-title":"Mechanisms of airway remodeling converge at the critical point of bronchoconstriction in asthma","volume":"10","author":"Winkler","year":"2022","journal-title":"Ann. Transl. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2147\/JAA.S267222","article-title":"Pathobiology of Airway Remodeling in Asthma: The Emerging Role of Integrins","volume":"15","author":"Joseph","year":"2022","journal-title":"J. Asthma Allergy"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jaci.2005.07.011","article-title":"Airway remodeling contributes to the progressive loss of lung function in asthma: An overview","volume":"116","author":"Pascual","year":"2005","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.jaci.2021.10.001","article-title":"Advances in asthma: New understandings of asthma\u2019s natural history, risk factors, underlying mechanisms, and clinical management","volume":"148","author":"Miller","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jaip.2024.11.005","article-title":"Cough-Variant Asthma: A Review of Clinical Characteristics, Diagnosis, and Pathophysiology","volume":"13","author":"Cox","year":"2025","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1164\/ajrccm.162.supplement_1.maic-2","article-title":"The Role of Inflammation in Airway Disease: Remodeling","volume":"162","author":"Tiddens","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jaci.2023.06.005","article-title":"Eosinophils and tissue remodeling: Relevance to airway disease","volume":"152","author":"Siddiqui","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1111\/all.15693","article-title":"Factors associated with suboptimal response to monoclonal antibodies in severe asthma","volume":"78","author":"Urrutia","year":"2023","journal-title":"Allergy"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/all.16382","article-title":"Biologics and airway remodeling in asthma: Early, late, and potential preventive effects","volume":"80","author":"Varricchi","year":"2025","journal-title":"Allergy"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12931-024-02812-3","article-title":"Barriers to clinical remission in severe asthma","volume":"25","author":"Farinha","year":"2024","journal-title":"Respir. Res. [Internet]"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2102583","DOI":"10.1183\/13993003.02583-2021","article-title":"Asthma remission: What is it and how can it be achieved?","volume":"60","author":"Thomas","year":"2022","journal-title":"Eur. Respir. J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1164\/rccm.202311-2192OC","article-title":"Exploring Definitions and Predictors of Severe Asthma Clinical Remission after Biologic Treatment in Adults","volume":"210","author":"Scelo","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1164\/rccm.202407-1428ED","article-title":"What Harm Are We Doing to Our Patients with Asthma by Using High-Dose Inhaled Corticosteroids?","volume":"211","author":"Sin","year":"2025","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1164\/rccm.202402-0368OC","article-title":"Association of Dose of Inhaled Corticosteroids and Frequency of Adverse Events","volume":"211","author":"Bloom","year":"2025","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease","volume":"356","author":"Calverley","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic Therapies for Severe Asthma. Taichman DB, editor","volume":"386","author":"Brusselle","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"112189","DOI":"10.1016\/j.intimp.2024.112189","article-title":"Precision medicine for severe asthma\u2014Biological targeted therapy","volume":"134","author":"Sun","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Pelaia, C., Crimi, C., Vatrella, A., Tinello, C., Terracciano, R., and Pelaia, G. (2020). Molecular Targets for Biological Therapies of Severe Asthma. Front. Immunol. [Internet], 11, Available online: https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.603312\/full.","DOI":"10.3389\/fimmu.2020.603312"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3325\/cmj.2025.66.3","article-title":"Effectiveness of biological therapy in severe asthma: A retrospective real-world study","volume":"66","author":"Lampalo","year":"2025","journal-title":"Croat. Med. J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/all.14221","article-title":"Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines\u2014Ecommendations on the use of biologicals in severe asthma","volume":"75","author":"Agache","year":"2020","journal-title":"Allergy"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-154-9-201105030-00002","article-title":"Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy: A Randomized Trial","volume":"154","author":"Hanania","year":"2011","journal-title":"Ann. Intern. Med."},{"key":"ref_24","unstructured":"The Cochrane Collaboration (2006). Anti-IgE for chronic asthma in adults and children. Cochrane Database of Systematic Reviews [Internet], John Wiley & Sons, Ltd.. Available online: https:\/\/doi.wiley.com\/10.1002\/14651858.CD003559.pub3."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1378\/chest.10-1194","article-title":"Efficacy and Safety of Subcutaneous Omalizumab vs Placebo as Add-on Therapy to Corticosteroids for Children and Adults With Asthma","volume":"139","author":"Rodrigo","year":"2011","journal-title":"Chest"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): A randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jaci.2016.08.008","article-title":"Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma","volume":"139","author":"Yancey","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/all.15867","article-title":"Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients","volume":"79","author":"Thomas","year":"2024","journal-title":"Allergy"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Pavord, I., Gardiner, F., Heaney, L.G., Domingo, C., Price, R.G., Pullan, A., Oppenheimer, J., Brusselle, G., Nagase, H., and Chupp, G. (2023). Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1150162"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1016\/j.jaip.2024.08.033","article-title":"Long-Term Clinical and Sustained REMIssion in Severe Eosinophilic Asthma Treated With Mepolizumab: The REMI-M Study","volume":"12","author":"Crimi","year":"2024","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: Results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s40265-017-0740-2","article-title":"Reslizumab in Eosinophilic Asthma: A Review","volume":"77","author":"Deeks","year":"2017","journal-title":"Drugs"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): A randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): A randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral Glucocorticoid\u2013Sparing Effect of Benralizumab in Severe Asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S2213-2600(21)00352-0","article-title":"Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): A multicentre, open-label, single-arm study","volume":"10","author":"Gurnell","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.jaip.2023.03.009","article-title":"Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy","volume":"11","author":"Louis","year":"2023","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s12325-018-0702-4","article-title":"Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy\/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma","volume":"35","author":"Busse","year":"2018","journal-title":"Adv. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jaip.2024.10.009","article-title":"Dupilumab Induces Long-Term On-Treatment Clinical Remission in Patients With Type 2 Asthma","volume":"13","author":"Pavord","year":"2025","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1164\/rccm.202210-2005OC","article-title":"Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials","volume":"208","author":"Corren","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S2213-2600(22)00492-1","article-title":"Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): A randomised, placebo-controlled extension study","volume":"11","author":"Wechsler","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2400316","DOI":"10.1183\/13993003.00316-2024","article-title":"Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: Results over 2 years from the NAVIGATOR and DESTINATION studies","volume":"64","author":"Wechsler","year":"2024","journal-title":"Eur. Respir. J."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Oishi, K., Hamada, K., Murata, Y., Matsuda, K., Ohata, S., Yamaji, Y., Asami-Noyama, M., Edakuni, N., Kakugawa, T., and Hirano, T. (2023). A Real-World Study of Achievement Rate and Predictive Factors of Clinical and Deep Remission to Biologics in Patients with Severe Asthma. J. Clin. Med., 12.","DOI":"10.3390\/jcm12082900"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.chest.2023.04.028","article-title":"Are We Ready for Asthma Remission as a Clinical Outcome?","volume":"164","author":"Lugogo","year":"2023","journal-title":"Chest"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2300819","DOI":"10.1183\/13993003.00819-2023","article-title":"Clinical remission in severe asthma with biologic therapy: An analysis from the UK Severe Asthma Registry","volume":"62","author":"McDowell","year":"2023","journal-title":"Eur. Respir. J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1016\/j.jaip.2023.05.047","article-title":"Response to Biologics and Clinical Remission in the Adult German Asthma Net Severe Asthma Registry Cohort","volume":"11","author":"Milger","year":"2023","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"107348","DOI":"10.1016\/j.rmed.2023.107348","article-title":"Severe asthma clinical remission after biologic treatment with anti-IL4\/IL13: A real-life experience","volume":"217","author":"Portacci","year":"2023","journal-title":"Respir. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.chest.2023.10.046","article-title":"Clinical Response and Remission in Patients With Severe Asthma Treated With Biologic Therapies","volume":"165","author":"Hansen","year":"2024","journal-title":"Chest"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jaip.2020.07.055","article-title":"Blood Eosinophil Count as a Predictor of Lung Function Decline in Healthy Individuals","volume":"9","author":"Lee","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1183\/09031936.00135907","article-title":"Exhaled nitric oxide predicts lung function decline in difficult-to-treat asthma","volume":"32","author":"Sterk","year":"2008","journal-title":"Eur. Respir. J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.rmed.2019.04.020","article-title":"Increase in blood eosinophils during follow-up is associated with lung function decline in adult asthma","volume":"152","author":"Graff","year":"2019","journal-title":"Respir. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.chest.2019.10.053","article-title":"Characterization of Severe Asthma Worldwide","volume":"157","author":"Wang","year":"2020","journal-title":"Chest"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1164\/rccm.202502-0504ED","article-title":"The Rapidly Evolving Landscape of Asthma Therapies Is Exhilarating, Yet a Lack of Innovation in Clinical Trial Design Makes Feasibility A Real Concern","volume":"211","author":"Lugogo","year":"2025","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jama.2018.2757","article-title":"Association of Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists With Asthma Control in Patients With Uncontrolled, Persistent Asthma: A Systematic Review and Meta-analysis","volume":"319","author":"Sobieraj","year":"2018","journal-title":"JAMA"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Kew, K.M., and Dahri, K. (2016). Long-Acting Muscarinic Antagonists (LAMA) Added to Combination Long-Acting Beta2-Agonists and Inhaled Corticosteroids (LABA\/ICS) Versus LABA\/ICS for Adults with Asthma. Cochrane Airways Group, Editor. Cochrane Database Syst. Rev. [Internet], 2016, Available online: http:\/\/doi.wiley.com\/10.1002\/14651858.CD011721.pub2.","DOI":"10.1002\/14651858.CD011721.pub2"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Bucchieri, S., Alfano, P., Audino, P., Cibella, F., Fazio, G., Marcantonio, S., and Cuttitta, G. (2021). Lung Function Decline in Adult Asthmatics-A 10-Year Follow-Up Retrospective and Prospective Study. Diagnostics, 11.","DOI":"10.3390\/diagnostics11091637"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e028150","DOI":"10.1136\/bmjopen-2018-028150","article-title":"Rate of normal lung function decline in ageing adults: A systematic review of prospective cohort studies","volume":"9","author":"Thomas","year":"2019","journal-title":"BMJ Open."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"214","DOI":"10.4168\/aair.2024.16.3.214","article-title":"Biologics in Severe Asthma: An Ideal Choice for Achieving Control","volume":"16","author":"Kim","year":"2024","journal-title":"Allergy Asthma. Immunol. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.anai.2016.09.006","article-title":"Evaluation of long-term safety and efficacy of omalizumab in elderly patients with uncontrolled allergic asthma","volume":"117","author":"Tat","year":"2016","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"A4636","DOI":"10.1016\/j.chest.2024.06.2809","article-title":"long-term safety of biologics in asthma: A systematic literature review","volume":"166","author":"Benson","year":"2024","journal-title":"Chest"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/MCP.0000000000001067","article-title":"Long-term safety, durability of response, cessation and switching of biologics","volume":"30","author":"Mohan","year":"2024","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12948-015-0016-x","article-title":"Choosing wisely: Practical considerations on treatment efficacy and safety of asthma in the elderly","volume":"13","author":"Scichilone","year":"2015","journal-title":"Clin. Mol. Allergy"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/17476348.2023.2215432","article-title":"Diagnostic and therapeutic approaches for elderly asthma patients: The importance of multidisciplinary and multidimensional management","volume":"17","author":"Benfante","year":"2023","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1080\/17476348.2024.2444331","article-title":"Polypharmacy in older patients with asthma: Hidden risks and opportunities for improvement","volume":"18","author":"Tomasello","year":"2024","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2017.04.009","article-title":"Oral corticosteroid exposure and adverse effects in asthmatic patients","volume":"141","author":"Sullivan","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/JAA.S176026","article-title":"Adverse outcomes from initiation of systemic corticosteroids for asthma: Long-term observational study","volume":"11","author":"Price","year":"2018","journal-title":"J. Asthma Allergy"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"j1415","DOI":"10.1136\/bmj.j1415","article-title":"Short term use of oral corticosteroids and related harms among adults in the United States: Population based cohort study","volume":"357","author":"Waljee","year":"2017","journal-title":"BMJ"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): Results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"A5231","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A5231","article-title":"Tezepelumab Reduces and Eliminates OCS Use in OCS-Dependent Patients With Severe Asthma: Primary Results From the Phase 3b WAYFINDER Study","volume":"211","author":"Jackson","year":"2025","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2401461","DOI":"10.1183\/13993003.01461-2024","article-title":"A proof-of-mechanism trial in asthma with lunsekimig, a bispecific NANOBODY molecule","volume":"65","author":"Deiteren","year":"2025","journal-title":"Eur. Respir. J."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Tomasello, A., Szefler, S.J., and Cahill, K.N. (2025). Emerging systemic treatments for asthma and allergic diseases: New tricks, same dog?. J. Allergy Clin. Immunol. Pract.","DOI":"10.1016\/j.jaip.2025.08.022"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0140-6736(17)30879-6","article-title":"After asthma: Redefining airways diseases","volume":"391","author":"Pavord","year":"2018","journal-title":"Lancet"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jaci.2018.08.031","article-title":"Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison","volume":"143","author":"Busse","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jaip.2021.11.016","article-title":"The Role of Comorbidities in Difficult-to-Control Asthma in Adults and Children","volume":"10","author":"Gaffin","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41533-020-00194-9","article-title":"Impact of comorbid conditions on asthmatic adults and children","volume":"30","author":"Kaplan","year":"2020","journal-title":"npj Prim Care Respir. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/MCP.0000000000001162","article-title":"Comorbidities and multimorbidity in asthma","volume":"31","author":"Maselli","year":"2025","journal-title":"Curr. Opin. Pulm. Med."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/10\/1797\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T08:54:55Z","timestamp":1759740895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/10\/1797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":80,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["medicina61101797"],"URL":"https:\/\/doi.org\/10.3390\/medicina61101797","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]}}}